IRVINE, Calif.--(BUSINESS WIRE)--
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
glaucoma and other diseases of the eye, today announced the appointments
of Jessica Crespo, CPA, as Director of Accounting, Minh Lu as Director
of Supply Chain, and Lorcan O'Toole as Operations Director for the Aerie
plant in Athlone, Ireland.
In connection with the acceptance of their positions, Ms. Crespo, Mr.
Lu, and Mr. O'Toole on a combined basis will receive awards totaling
48,000 stock options. The stock options will vest over 4 years, with 25%
vesting on the first anniversary of the hire date and the remainder
vesting ratably on each of the subsequent 36 monthly anniversaries of
the hire date. These awards were made outside of Aerie's
stockholder-approved equity incentive plan and were approved by the
Company's Compensation Committee as an inducement material to Ms.
Crespo, Mr. Lu, and Mr. O'Toole entering into employment with the
Company in reliance on NASDAQ Listing Rule 5635(c)(4), which requires
this public announcement.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class therapies
for the treatment of patients with glaucoma and other diseases of the
eye. Aerie's two current product candidates are once-daily intraocular
pressure lowering therapies with novel mechanisms of action to treat
patients with glaucoma or ocular hypertension. The NDA for RhopressaTM
(netarsudil ophthalmic solution) 0.02% was submitted to the FDA in
February 2017, and, in May 2017, the FDA set the PDUFA goal date for the
completion of the FDA's review of the RhopressaTM NDA for
February 28, 2018. Aerie's second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is a
fixed dose combination of RhopressaTM and widely prescribed
PGA latanoprost, currently has two Phase 3 registration trials underway,
named Mercury 1 and Mercury 2. If these trials are successful, a RoclatanTM
NDA submission is expected to take place in late 2017 or early 2018.
Aerie is also focused on the development of additional product
candidates and technologies in ophthalmology.
This press release contains forward-looking statements for purposes of
the safe harbor provisions of the Private Securities Litigation Reform
Act of 1995. We may, in some cases, use terms such as "predicts,"
"believes," "potential," "proposed," "continue," "estimates,"
"anticipates," "expects," "plans," "intends," "may," "could," "might,"
"will," "should," "exploring," "pursuing" or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Forward-looking statements include
statements regarding our intentions, beliefs, projections, outlook,
analyses or current expectations concerning, among other things: the
success, timing and cost of our ongoing and anticipated preclinical
studies and clinical trials for our current and potential future product
candidates, including statements regarding the timing of initiation and
completion of the studies and trials; our expectations regarding the
clinical effectiveness of our product candidates and results of our
clinical trials; the timing of and our ability to request, obtain and
maintain U.S. Food and Drug Administration or other regulatory authority
approval of, or other action with respect to, our product candidates,
including the expected timing of NDA filings for our product candidates;
our expectations regarding the commercialization and manufacturing of
our product candidates; the potential advantages of our product
candidates; our plans to pursue development of our product candidates
for additional indications and other therapeutic opportunities; our
plans to explore possible uses of our existing proprietary compounds
beyond glaucoma; our ability to protect our proprietary technology and
enforce our intellectual property rights; and our expectations regarding
strategic operations, including our ability to in-license or acquire
additional ophthalmic products or product candidates. By their nature,
forward-looking statements involve risks and uncertainties because they
relate to events, competitive dynamics, industry change and other
factors beyond our control, and depend on regulatory approvals and
economic and other environmental circumstances that may or may not occur
in the future or may occur on longer or shorter timelines than
anticipated. We discuss many of these risks in greater detail under the
heading "Risk Factors" in the quarterly and annual reports that we file
with the Securities and Exchange Commission (SEC). Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ materially
from the forward-looking statements contained in this press release. Any
forward-looking statements that we make in this press release speak only
as of the date of this press release. We assume no obligation to update
our forward-looking statements whether as a result of new information,
future events or otherwise, after the date of this press release.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170516005055/en/
Richard Rubino, 908-947-3540
McClellan, Inc., on behalf of Aerie Pharmaceuticals
Source: Aerie Pharmaceuticals, Inc.
News Provided by Acquire Media